552 related articles for article (PubMed ID: 16754938)
21. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
[TBL] [Abstract][Full Text] [Related]
22. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
23. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
24. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
25. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
[TBL] [Abstract][Full Text] [Related]
26. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
27. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
29. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
30. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
32. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
33. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
34. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
36. Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
[TBL] [Abstract][Full Text] [Related]
37. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Smyth JF; Gourley C; Walker G; MacKean MJ; Stevenson A; Williams AR; Nafussi AA; Rye T; Rye R; Stewart M; McCurdy J; Mano M; Reed N; McMahon T; Vasey P; Gabra H; Langdon SP
Clin Cancer Res; 2007 Jun; 13(12):3617-22. PubMed ID: 17575226
[TBL] [Abstract][Full Text] [Related]
38. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.
Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Takata D; Rokutanda N; Nagaoka R; Oyama T; Iino Y; Morishita Y
Oncol Rep; 2005 Nov; 14(5):1109-16. PubMed ID: 16211272
[TBL] [Abstract][Full Text] [Related]
39. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
[TBL] [Abstract][Full Text] [Related]
40. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Bowman A; Gabra H; Langdon SP; Lessells A; Stewart M; Young A; Smyth JF
Clin Cancer Res; 2002 Jul; 8(7):2233-9. PubMed ID: 12114425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
